- Home
- ELBM vs PULM Comparison
ELBM vs PULM Comparison
Compare ELBM & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- PULM
- Stock Information
- Founded
- ELBM 2011
- PULM 2003
- Country
- ELBM Canada
- PULM United States
- Employees
- ELBM N/A
- PULM N/A
- Industry
- ELBM Industrial Machinery/Components
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- PULM Health Care
- Exchange
- ELBM Nasdaq
- PULM Nasdaq
- Market Cap
- ELBM 19.2M
- PULM 18.3M
- IPO Year
- ELBM N/A
- PULM N/A
- Fundamental
- Price
- ELBM $1.64
- PULM $4.94
- Analyst Decision
- ELBM Strong Buy
- PULM
- Analyst Count
- ELBM 2
- PULM 0
- Target Price
- ELBM $2.20
- PULM N/A
- AVG Volume (30 Days)
- ELBM 20.5M
- PULM 18.5K
- Earning Date
- ELBM 11-14-2025
- PULM 10-16-2025
- Dividend Yield
- ELBM N/A
- PULM N/A
- EPS Growth
- ELBM N/A
- PULM N/A
- EPS
- ELBM N/A
- PULM N/A
- Revenue
- ELBM N/A
- PULM $3,000.00
- Revenue This Year
- ELBM N/A
- PULM N/A
- Revenue Next Year
- ELBM N/A
- PULM $134.88
- P/E Ratio
- ELBM N/A
- PULM N/A
- Revenue Growth
- ELBM N/A
- PULM N/A
- 52 Week Low
- ELBM $0.77
- PULM $1.96
- 52 Week High
- ELBM $8.70
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- ELBM 48.65
- PULM 52.93
- Support Level
- ELBM $1.60
- PULM $4.58
- Resistance Level
- ELBM $2.64
- PULM $5.24
- Average True Range (ATR)
- ELBM 1.06
- PULM 0.28
- MACD
- ELBM -0.09
- PULM 0.02
- Stochastic Oscillator
- ELBM 7.34
- PULM 47.34
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).